Journal
KIDNEY INTERNATIONAL
Volume 98, Issue 2, Pages 294-309Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2020.04.020
Keywords
acute kidney disease; acute kidney injury; fluid management; nephrotoxicity; renal replacement therapy; risk stratification
Categories
Funding
- KDIGO
- Akebia Therapeutics
- Angion
- AMPharma
- AstraZeneca
- Astute Medical
- Atox Bio
- Baxter
- bioMerieux
- BioPorto
- Boehringer Ingelheim
- CytoSorbents
- Edwards
- Fresenius Medical Care
- GE Healthcare
- Grifols
- Kyowa Kirin
- Novartis
- NxStage
- Outset
- Potrero
Ask authors/readers for more resources
In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available